Saratov JOURNAL of Medical and Scientific Research

Ocular rosacea: etiology, pathophysiological mechanisms, clinical manifestations and main methods of treatment

Year: 2018, volume 14 Issue: №4 Pages: 946-949
Heading: Ophtalmology Article type: Review
Authors: Mustafina G.R., Khismatullina Z.R., Sattarova R.R.
Organization: Bashkir State Medical University of the Russian Health Care, ZAO Optimedservis

The review of the literature covers etiology, pathophysiological mechanisms, clinical manifestations and the main methods of treatment of ocular rosacea. Rosacea is one of the common chronic skin diseases with a diverse clinical picture. Ophthalmological manifestations of the disease are associated with affect to the cornea, conjunctiva and eyelids. The etiology and pathogenesis of the disease is not fully understood currently. Pathological processes in ocular rosacea are associated with disorders in vascular, immune and nervous systems, as well as with the influence of a number of microorganisms. In the treatment of ocular rosacea drugs of local and systemic action are used. Systemic therapy includes tetracycline and macrolide antibiotics and angioprotectors. Local therapy is associated with the use of artificial tears, anti-inflammatory drugs and local antibiotics. In severe cases of ocular rosacea surgical management is required.

1 Rolleston JD. A Note on the Early History of Rosacea. Proceedings of the Royal Society of Medicine 1933; 26 (4): 327-9
2 Kubanova AA, Makhakova YuB. Rosacea: prevalence, pathogenesis, particular features of clinical manifestations. Journal of Dermatology and Venerology 2015; (3): 36-45
3 Lazaridou Е, Fotiadou С, Ziakas NG, et al. Clinical and laboratory study of ocular rosacea in northern Greece. Journal of the European Academy of Dermatology and Venerology 2011; 25(12): 1428-31
4 Borrie P. Rosacea with special reference to its ocular manifestations. British Journal of Dermatology 1953; 65 (12): 458-63
5 Federal clinical guidelines: Dermatovenerology-2015: Diseases of the skin. Sexually transmitted infections. 5th ed. M.: Business Express, 2016; 768 p.
6 Ghanem VC, Mehra N, Wong S, et al. The prevalence of ocular signs in acne rosacea: comparing patients from ophthalmology and dermatology clinics. Cornea 2003; 22 (3): 230-3
7 Barton K, Monroy DC, NavaA, etal. Inflammatory cytokines in the tears of patients with ocular rosacea. Ophthalmology 1997; 104(11): 1868-74
8 Sobrin L, Liu Z, Monroy DC, et al. Regulation of MMP-9 activity in human tear fluid and corneal epithelial culture supernatant. Investigative ophthalmology and visual science 2000; 41 (7): 1703-9.9 Yildirim Y, Olcucu O, Agca A, et al. Topographic and biomechanical evaluation of corneas in patients with ocular rosacea. Cornea 2015; 34 (3): 313-7
10 Gallo RL, Granstein RD, Kang S, et al. Standard classification and pathophysiology of rosacea: The 2017 update by the National Rosacea Society Expert Committee. Journal of the American Academy of Dermatology 2018; 78 (1): 148-55
11 Redfern RL, Reins RY, McDermott AM. Toll-like receptor activation modulates antimicrobial peptide expression by ocular surface cells. Experimental eye research 2011; 92 (3): 209-20
12 Ueta M, Kinoshita S. Innate immunity of the ocular surface. Brain research bulletin 2010; 81 (2-3): 219-28
13 Vieira ACC, Hufling-Lima AL, Mannis MJ. Ocular rosacea: a review. Arquivos brasileiros de oftalmologia 2012; 75 (5): 363-9
14 Dakovic Z, Vesic S, Vukovic J, et al. Ocular rosacea and treatment of symptomatic Helicobacter pylori infection: a case series. Acta dermatovenerologica Alpina, Pannonica, et Adriatica 2007; 16 (2): 83-6
15 Li J, O'Reilly N, Sheha H, et al. Correlation between ocular Demodex infestation and serum immunoreactivity to Bacillus proteins in patients with facial rosacea. Ophthalmology 2010; 117 (5): 870-7
16 Starr PA, Macdonald A. Oculocutaneous aspects of rosacea. Proceedings of the Royal Society of Medicine 1969; 62 (1):9-11
17 Ravage ZB, Beck АР, Macsai MS, et al. Ocular rosacea can mimic trachoma: a case of cicatrizin conjunctivitis. Cornea 2004; 23 (6): 630-1
18 Akpek EK, Merchant A, Pinar V, et al. Ocular rosacea: patient characteristics and follow-up. Ophthalmology 1997; 104 (11): 1863-7
19 Gudmundsen KJ, O'Donnell BF, Powell FC. Schirmer testing for dry eyes in patients with rosacea. Journal of the American Academy of Dermatology 1992; 26 (2): 211-4
20 Sobolewska B, Doycheva D, Deuter C, et al. Treatment of ocular rosacea with once-daily low-dose doxycycline. Cornea 2014; 33(3): 257-60
21 Mantelli F, Di Zazzo A, Sacchetti M, et al. Topical azithromycin as a novel treatment for ocular rosacea. Ocular immunology and inflammation 2013; 215): 371-7
22 Seal DV, Wright P, Ficker L, et al. Placebo controlled trial of fusidicacid gel and oxytetracycline for recurrent blepharitis and rosacea. British journal of ophthalmology 1995; 79 (1): 42-5
23 Lee H, Min K, Kim EK, et al. Minocycline controls clinical outcomes and inflammatory cytokines in moderate and severe meibomian gland dysfunction. American journal of ophthalmology 2012; 154 (6): 949-57
24 Arman A, Demirseren DD, Takmaz T. Treatment of ocular rosacea: comparative study of topical cyclosporine and oral doxycycline. International journal of ophthalmology 2015; 8 (3): 544
25 Al Arfaj K, Al Zamil W. Spontaneous corneal perforation in ocular rosacea. Middle East African journal of ophthalmology 2010; 17(2): 186.

2018_4-2_946-949.pdf253.28 KB

No votes yet